Supernus Announces Third Quarter 2019 Financial Results and Topline Data from Phase III Study of SPN-810 for Treatment of Impulsive Aggression (IA) in ADHD Patients
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
| SUPERNUS PHARM (NASDAQ: SUPN) | Delayed: 42.07 +0.86 (2.09%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $41.21 | 52 Week High | $26.84 | |||
| Open | $41.52 | 52 Week Low | $9.51 | |||
| Day High | $42.09 | P/E | N/A | |||
| Day Low | $40.73 | EPS | $-2.62 | |||
| Volume | 937,420 | |||||
